'Branded generics' as a strategy to limit cannibalization of pharmaceutical markets

Article Abstract:

Pharmaceutical companies introduce generic versions of their patented drugs to manipulate the balance in market share between generics and brand drugs. The strategy is to sell the generics at a high price, influencing consumers to buy the branded ones instead, which in turn, increases revenue for the company in the branded segment. The implications of branded generic technique are evaluated.

Sales & consumption, Product introduction, Pharmaceutical Preparation Manufacturing, New Products/Services, Market share, Generic Drugs, Brand name products, Brand names, Company market share, Industry sales and revenue

---

Uncertainty and choice: the challenges of pharmaceutical efficacy, safety, and cost

Article Abstract:

The price hike in healthcare and particularly that in medicine is allegedly caused by fewer new drugs that are being developed. Safety is another issue being faced by the industry as government agencies are speeding up approvals at the expense of therapeutic benefits. The importance of monitoring the effects of the approved medicines is discussed.

General services, Government regulation, Safety and security measures, Licensing, certification and accreditation

---

Similar abstracts:

• Abstracts: Entry and competition in generic biologics. A primer on the economics of re-importation of prescription drugs

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.